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To evaluate the National Comprehensive Cancer Network (NCCN) International Prognostic Index (IPI), we
analyzed 284 patients treated with the combination of rituximab, cyclophosphamide, doxorubicin,
vincristine, and prednisone (R-CHOP) in our institution in Japan. Their 5-year overall survival (OS) by risk
level was 80.7%, 74.8%, 55.4% and 67.5% (P¼0.005); and their 5-year progression-free survival (PFS) was
76.8%, 78.6%, 63.7% and 58.3% (P¼0.0722). The NCCN-IPI is a simple scale that uses conventional clinical
factors, but did not reﬂect survival in our cohort. The NCCN-IPI may require further evaluation for dif-
ferent regions and ethnicities before adopting it for routine clinical use.
& 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Recently Zhou et al. developed the new National Comprehen-
sive Cancer Network (NCCN)- International Prognostic Index (IPI)
to predict survival in the rituximab era more accurately than the
older IPI system [1]. Although reports that used the same prog-
nostic stratiﬁcation have since been published from various geo-
graphic regions, whether these results can be extrapolated to
different ethnic populations is unclear. We therefore aimed to
validate the NCCN-IPI in the presumably less selected population
of Japanese patients with diffuse large B cell lymphoma (DLBCL).2. Materials and methods
We included 284 patients who were consecutively diagnosed
with DLBCL and treated with ﬁrst-line rituximab, cyclopho-
sphamide, doxorubicin, vincristine, and prednisone (r-CHOP), or
R-CHOP-like treatment at Kansai Medical University Hospital
during 2006–2014 in this retrospective analysis. This study was
approved by the Ethics Committee of Kansai Medical University.
Patient survival was analyzed with the Kaplan–Meier method, andLtd. This is an open access article u
al Medicine, Kansai Medical
10, Japan.
ya).results were compared by log-rank and Cox proportional hazards
models. Po0.05 was considered signiﬁcant. All statistical analyses
were performed using EZR (modiﬁed R software, Saitama Medical
Center, Jichi Medical University, Saitama, Japan).3. Results
Mean age of these patients was 67 years old (range: 20–91
years). The NCCN-IPI classiﬁed 11% of patients being as low risk,
36% as low-intermediate (LI), 47% as high-intermediate (HI) and 6%
as high risk (Table 1). Compared to the older IPI, fewer patients
were classiﬁed as low- or high-risk and more as LI and HI. The
NCCN-IPI failed to identify four prognostic groups of patients in
our cohort. Our patients’ 5-year overall survival (OS) rates were
low-risk: 80.7%; LI: 74.8%; HI: 55.4%; and high-risk: 67.5%
(P¼0.005) (Fig. 1.(A)). Their 5-year progression-free survival (PFS)
rates were low-risk: 76.8%; LI: 78.6%; HI: 63.7%; and high-risk:
58.3% (P¼0.0722) (Fig. 2.(A)). For patients who did not receive
upfront autologous hematopoietic stem cell transplantation
(ASCT), the 5-year OS rates were low-risk: 80.7%; LI: 76.5%; HI:
53.2%, and high-risk: 63.5% (P¼0.00137) (Fig. 1.(B)). Their 5-year
PFS rates were low-risk: 76.8%; LI: 80.3%; HI: 58.7%; and high-risk:
63.6% (P¼0.123) (Fig. 2.(B)).
In multivariate analysis, low albumin level (o3.5 g/dl) was
an independent predictor of shorter OS, although lactate dehy-
drogenase (LDH), hemoglobin (Hb), C-reactive protein (CRP),nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Patients' characteristics.
No. of patients (n) 284
Median age, range(y/o) 67(20–91)
40≧(%) 5
440 to ≦60(%) 23
460 to ≦75(%) 49
475 (%) 23
Male sex (%) 61
IPI/aaIPI (%)
Low 37
Low-intermediate 16
High-intermediate 19
High 28
NCCN-IPI (%)
Low 11
Low-intermediate 36
High-intermediate 47
High 6
Stage(%)
Ⅰ 23
Ⅱ 14
Ⅲ 19
Ⅳ 44
Elevated LDH level (%) 48
Extranodal disease 41 (%) 40
upfront ASCT(%) 9
LDH: lactate dehydrogenase
ASCT: autologous hematopoietic stem cell
transplantation
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(Table 2).Fig. 1. Five-year OS using NCCN-IPI were 80.7%, 74.8%, 55.4%, 67.5% (p¼0.005) (A).
Patients without upfront ASCT(B) were 80.7%, 76.5%, 53.2%, 63.5%(p¼0.00137) (B).
The result revealed that patients were statistically stratiﬁed into 4-risk groups,
however HI was the worst prognosis.
Table 2
Multivariate analysis.
Parameter HR 95%CI p value
LDH 1.106 0.681–1.793 0.684
Alb 1.949 1.121–3.386 0.018
Hb 1.088 0.666–1.775 0.737
CRP 0.986 0.333–2.912 0.980
Age 1.177 0.712–1.947 0.525
Sex 1.325 0.828–2.119 0.241
Stage 1.642 0.866–3.109 0.128
extra node 1.526 0.910–2.557 0.109
upfront ASCT 0.404 0.151–1.073 0.069
LDH: lactate dehydrogenase
Alb: albumin
Hb: hemoglobin
CRP: C-reactive protein
ASCT: autologous hematopoietic stem cell transplantation4. Discussion
Although the NCCN-IPI was developed to improve stratiﬁcation
of high-risk patients with DLBCL (i.e., whose 5-year OSo50%), it
failed to detect them in our analysis; the HI group had shorter
5-year OS than the high-risk group (Fig. 1 A.).
In our institute, most eligible high-risk or HI patients were
treated with upfront ASCT, which we assumed would improve
their survival. When we excluded these patients from our analysis,
the poorer 5-year OS for the HI group compared with the high-risk
group was even more pronounced (Fig. 1 B.).
As the NCCN-IPI attaches more weight on age in the 4 risk
groups, we supposed that its failure to predict outcome in this
study was because our patients were older than original cohort;
thus prognoses of patients whose high scores were due to age
rather than tumor burden (as indicated by LDH or stage) might not
be accurately predicted in the NCCN-IPI system. Some reports
described results similar to ours, showing that NCCN-IPI failed to
accurately predict outcomes for elderly patients [4,7].
Aside from LDH, information about how other important para-
meters affect NCCN-IPI results have not been published, as far as we
know. Hemoglobin [2], albumin [3,4], and CRP [5] have been found to
be independent prognostic factors in aggressive lymphoma. As these
reported parameters were routinely available in our patients’ records,
we analyzed their effects on OS, using multivariate analysis; however,
we found only low albumin levels to be a signiﬁcant predictor of worse
5-year OS. As albumin is usually assessed, quite easily and cheaply in
standard blood laboratory tests, and is highly reproducible, it could be
an important predictor, and be incorporated into a prognostic index.
Although the NCCN-IPI is a promising simple scale based on
conventional clinical factors, its usefulness remains controversial[6,7]. It should be evaluated in populations of different regions and
ethnicities before adopting it for routine clinical use.
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Fig. 2. Five-year PFS using NCCN-IPI were 78.6%, 76.8%, 63.7%, 58.3% (p¼0.0722)
(A). Patients without upfront ASCT(B) were 80.3%, 76.8%, 58.7%, 63.6%(p¼0.123)(B).
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